Dacarbazine for Injection, USP Now Available

Share Facebook icon Twitter icon Linkedin icon
May 13, 2024

Meitheal Pharmaceuticals (Meitheal) is pleased to announce that we have launched Dacarbazine for Injection, USP 200 mg per vial, in a pack of 10 single-dose vials.

ABOUT DACARBAZINE FOR INJECTION, USP

Dacarbazine for Injection is indicated in the treatment of metastatic malignant melanoma. In addition, Dacarbazine for Injection is also indicated for Hodgkin’s disease as a secondary line therapy when used in combination with other effective agents.

For full prescribing information, please click on the following link.


Learn more about Dacarbazine for Injection, USP

New Launches
Meitheal Pharmaceuticals has Ampicillin and Sulbactam for Injection, USP 15 g per PBP Now Available

Meitheal Pharmaceuticals has Ampicillin and Sulbactam for Injection, USP 15 g per PBP Now Available

 Cetrorelix Acetate for Injection Now Available

Cetrorelix Acetate for Injection Now Available
This Website Uses Cookies

This website uses cookies to help give you the best experience when you visit. By clicking “Accept Cookies,” you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and help us make improvements to our site. You can read more about our use of cookies in our Privacy Policy.

Manage Consent Preferences

Always Active

Necessary cookies enable core functionality such as security and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.

These cookies are set to provide quantitative measures of website visitors. Information collected with these cookies is used in operations to measure website performance. With the usage of these cookies we are able to count visits and traffic sources to improve our site. The data is collected in a way that does not directly identify anyone.
Accept all cookies Confirm my choices